Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

GDRX - GoodRx Holdings, Inc. So'nggi Yangiliklar | Finranks

Home

/

GDRX

G

GoodRx Holdings, Inc. (GDRX)

NMS – Real vaqt narxi. Valyuta: USD

3.62

-0.18 (-4.74%)

Bozor ochiq: Aug 12, 2026, 1:13 PM EDT

3.75

-0.05 (-1.32%)

Oldingi bozordan keyin: Aug 11, 2026, 7:41 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

GoodRx: Direct Brand Launches And New Subscription Plans Are Offering Hope

GoodRx has rebounded from $2.50 per share, showing renewed growth momentum and improved consumer traction. New offerings have contributed to GDRX's recent positive developments, but the stock's rapid appreciation reflects these improvements. I remain marginally more positive, yet GDRX still presents considerable risk, warranting a continued neutral rating.

Push for 'COMPETITIVE CASH PRICING': GoodRx CEO on TrumpRx partnership

Push for 'COMPETITIVE CASH PRICING': GoodRx CEO on TrumpRx partnership

GoodRx CEO Wendy Barnes discusses the company's partnership with TrumpRx and efforts to lower prescription drug costs on ‘The Claman Countdown.'

GoodRx Holdings, Inc. (GDRX) Q2 2026 Earnings Call Transcript

GoodRx Holdings, Inc. (GDRX) Q2 2026 Earnings Call Transcript

GoodRx Holdings, Inc. (GDRX) Q2 2026 Earnings Call Transcript

GoodRx Q2 Earnings Call Highlights

GoodRx Q2 Earnings Call Highlights

GoodRx NASDAQ: GDRX reported second-quarter 2026 revenue of $200.4 million and adjusted EBITDA of $63.7 million, representing a 31.8% adjusted EBITDA margin, as growth in its Pharma Direct and subscription businesses offset pressure in prescription transaction revenue.

GoodRx and Oscar Health Tout Tech as Consumer Needs Change

GoodRx and Oscar Health Tout Tech as Consumer Needs Change

The latest earnings from Oscar Health and GoodRx show both companies dealing with a changing customer base. The former company reported half-year earnings Thursday (Aug. 6) showing record profitability for the first six months of 2026, with revenues surging 70% to $4.9 billion.

GoodRx Holdings, Inc. (GDRX) Q2 Earnings Match Estimates

GoodRx Holdings, Inc. (GDRX) Q2 Earnings Match Estimates

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.08 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.09 per share a year ago.

GoodRx (GDRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

GoodRx (GDRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for GoodRx (GDRX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Videolar

Push for 'COMPETITIVE CASH PRICING': GoodRx CEO on TrumpRx partnership

Press-relizlar

GoodRx Reports Second Quarter 2026 Results

GoodRx Reports Second Quarter 2026 Results

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading platform for medication savings in the U.S., has released its financial results for the second quarter of 2026. Second Quarter 2026 Highlights Revenue of $200.4 million Net income of $8.5 million; Net income margin of 4.3% Adjusted Net Income1 of $26.8 million; Adjusted Net Income Margin1 of 13.4% Adjusted EBITDA1 of $63.7 million; Adjusted EBITDA Margin1 of 3.